Celularity Inc.
NASDAQ:CELUBiotechnology
+$1.22 today
- Market cap
- $52.97M
- Beta
- 0.54
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$3.58
Volume 0.00M
Average 0.13M
CELU EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Celularity Inc.NASDAQ: CELU
EPS (Diluted) · Q4 FY2025 · quarter ended Dec 2025
EPS (Diluted) remains negative
Q4 FY2025 EPS (Diluted) was -$0.95, compared with -$0.59 a year earlier. Trailing-twelve-month EPS (Diluted) was -$3.69.
Context
- EPS (Diluted) increased in 1 of the last 3 fiscal years.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 1 analysts of -$2.75 (+23.4%) for the fiscal year ending Dec 2026, a step up from the -35.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- -$0.95-8.0% QoQ
- Last fiscal yearDec 2025
- -$3.59-35.7% YoY
- LTMDec 2025
- -$3.69-39.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -59.7% | — | — |
| 1 year | -35.7% | +23.4% | +59.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (3.59) USD
- Year-over-year change
- -35.7%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.59) | -35.7% |
| FY2024 | 2024-12-31 | (2.64) | +76.0% |
| FY2023 | 2023-12-31 | (11.02) | -1263.4% |
| FY2022 | 2022-12-31 | 0.95 | +112.0% |
| FY2021 | 2021-12-31 | (7.87) | — |
EPS (Diluted) vs competitors
How CELU compares with its peers on the latest reported figures
- CELU's LTM Dec 2025 EPS (Diluted) of -$3.69 is the lowest of the 4 companies compared; the peer median is -$1.72.
- Its year-over-year change of -39.2% is the lowest of 4, against a peer median of +55.6%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $0.36 | +127.5% | — | |
| LTM Mar 2026 | -$1.72 | +26.5% | — | |
| LTM Mar 2026 | -$1.91 | +55.6% | — | |
| LTM Dec 2025 | -$3.69 | -39.2% | — | |
| Peer median (excluding CELU) | -$1.72 | +55.6% | — | |
Competitors are the stored peer set for CELU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 21.34M | 17.98M | 22.77M | 54.22M | 26.55M |
| Cost of Revenue | 9.65M | 19.67M | 16.02M | 14.99M | 6.36M |
| Gross Profit | 11.68M | (1.69M) | 6.76M | 39.23M | 20.19M |
| Gross Margin | 54.8% | -9.4% | 29.7% | 72.4% | 76.0% |
| Research & Development | 88.35M | 78.36M | 30.47M | 17.39M | 15.03M |
| Selling, General & Admin | 71.34M | 66.02M | 50.58M | 58.64M | 51.27M |
| Operating Expenses | 120.74M | 23.91M | 199.04M | 77.59M | 81.5M |
| Depreciation & Amortization | 8.82M | 9.44M | 9.32M | 7.92M | 7.3M |
| EBITDA | (88.11M) | (138.83M) | (183.95M) | (43.71M) | (77.66M) |
| EBITDA Margin | -413.0% | -772.4% | -807.8% | -80.6% | -292.5% |
| Operating Income | (109.06M) | (25.6M) | (192.29M) | (38.36M) | (61.31M) |
| Operating Margin | -511.2% | -142.4% | -844.4% | -70.7% | -230.9% |
| Interest Income | 332K | 365K | 320K | 331K | 262K |
| Interest Expense | 3.17M | 0 | 3.02M | 6.26M | 6.75M |
| Other Income / Expenses | 8.96M | 39.81M | (4M) | (19.53M) | (30.41M) |
| Income Before Tax | (100.1M) | 14.21M | (196.29M) | (57.89M) | (91.71M) |
| Pre-Tax Margin | -469.2% | 79.0% | -862.0% | -106.8% | -345.4% |
| Income Tax Expense | 20K | 13K | 10K | 0 | 3K |
| Net Income | (100.12M) | 14.19M | (196.3M) | (57.89M) | (91.8M) |
| Net Margin | -469.3% | 79.0% | -862.0% | -106.8% | -345.8% |
| EPS (Basic) | (7.87) | 1.01 | (11.02) | (2.64) | (3.59) |
| EPS (Diluted) | (7.87) | 0.95 | (11.02) | (2.64) | (3.59) |
| Weighted Avg Shares | 12.73M | 13.99M | 17.81M | 21.89M | 25.6M |
| Weighted Avg Shares (Diluted) | 12.73M | 14.98M | 17.81M | 21.89M | 25.6M |
Celularity Inc.
NASDAQ:CELU
Intrinsic Alpha fair value
Locked
Current Price
$1.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.